French Vasculitis Study Group
4
0
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 4 trials
100.0%
+13.5% vs industry average
100%
4 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
Role: collaborator
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Role: collaborator
Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.
Role: collaborator
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Role: collaborator
All 4 trials loaded